GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Orchid Pharma Ltd

Orchid Pharma Q2 FY27 Consolidated Net Sales at 34,126.66 lakhs, Profit Up

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 14 Nov 2026, 04:27 PM IST  ·  BSE ID: 5ed11f0e-4000-4bef-a8ce-33c05a3716c0
View Original BSE Filing (PDF)
💡
In Simple Terms
Orchid Pharma reported its quarterly financial results, showing significant sales and profit increases compared to the previous year.
🤖 AI Summary
  • Consolidated Net Sales for Q2 FY27 reached 34,126.66 lakhs Indian Rupees.
  • Consolidated Profit for Q2 FY27 was 2,859.41 lakhs Indian Rupees.
  • Basic Earnings per share (EPS) stood at Rs. 4.77 for the quarter ended September 30, 2026.
  • Unaudited Standalone and Consolidated Financial Results approved by Board on November 14, 2026.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Consolidated Net Sales Q2 FY27
34,126.66 lakhs
14.34%
Consolidated Net Sales Q2 FY26
29,845.86 lakhs
Consolidated Profit Q2 FY27
2,859.41 lakhs
Not comparable — limited prior period data.
Consolidated Profit Q2 FY26
(89.84) lakhs
Consolidated Basic EPS Q2 FY27
Rs. 4.77
Not comparable — limited prior period data.
Consolidated Basic EPS Q2 FY26
Rs. (0.15)
🏢 How This Affects the Company
📈
Business Impact
The increase in Net Sales to 34,126.66 lakhs Indian Rupees in Q2 FY27 indicates growth in the company's operational revenue streams. This enhances the company's market presence within its operational segments.
💰
Financial Impact
The Consolidated Profit of 2,859.41 lakhs Indian Rupees for Q2 FY27 marks a significant turnaround from a loss of (89.84) lakhs in the prior year, improving the company's earnings profile. This positively impacts the overall financial performance and balance sheet health.
👥 What This Means For Shareholders
✅
Action Required
No specific action is required from shareholders based on this financial results declaration.
👤
Who Is Affected
All shareholders are affected as the financial results provide an update on the company's performance, impacting the perceived value and future prospects of their holdings.
🔍
Management Signal
The approval of the unaudited financial results signals management's commitment to timely disclosure and adherence to regulatory requirements for financial reporting.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — evaluate sales and profit trend continuation.
Any updates on operational expansion or new product launches.
Changes in inventory levels — monitor impact on working capital management.
LOW RISK The filing reports strong financial results, indicating reduced immediate operational and financial risks.
💡 Investor Takeaway
Orchid Pharma reported Q2 FY27 consolidated net sales of 34,126.66 lakhs Indian Rupees, up from 29,845.86 lakhs Indian Rupees in Q2 FY26. Consolidated profit for the period was 2,859.41 lakhs Indian Rupees, a significant increase from a loss of (89.84) lakhs Indian Rupees in the comparable prior period.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated Profit for Q2 FY27 was 2,859.41 lakhs, a substantial improvement from a loss of (89.84) lakhs in Q2 FY26.
  • Consolidated Net Sales from operations for Q2 FY27 increased to 34,126.66 lakhs from 29,845.86 lakhs in Q2 FY26.
📅 Company Track Record
Orchid Pharma previously informed BSE on November 11, 2026, about the Board Meeting scheduled for November 14, 2026, to approve its Q2 FY27 financial results. This aligns with standard quarterly reporting cycles for the company.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What were Orchid Pharma's consolidated net sales in Q2 FY27?
Orchid Pharma's consolidated Net Sales from operations for the quarter ended September 30, 2026 (Q2 FY27) were 34,126.66 lakhs Indian Rupees.
What was Orchid Pharma's consolidated profit for Q2 FY27?
The consolidated Profit for the period (Q2 FY27) for Orchid Pharma was 2,859.41 lakhs Indian Rupees, compared to a loss of (89.84) lakhs Indian Rupees in the same period last year.
What is the Basic EPS for Orchid Pharma in Q2 FY27?
Orchid Pharma reported a Basic Earnings per Share (EPS) of Rs. 4.77 for the quarter ended September 30, 2026.
When were Orchid Pharma's Q2 FY27 financial results approved?
The Board of Directors of Orchid Pharma considered and approved the unaudited standalone and consolidated financial results for Q2 FY27 on November 14, 2026.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.

Live IPO, GMP and market updates on Telegram

IPO open and close dates, grey market premium moves, subscription figures, allotment and listing days, and the market updates worth knowing about, posted on the channel as they happen.

Join the channel